ACTA2抗体

+ +

•  

   

     Western blot analysis of anti-NMD3 Pab (Cat. #P30163) in mouse heart (left) and T47D (right)tissue lysates (35ug/lane). NMD3(arrow) was detected using the purified Pab.    

  
  

ACTA2 (Alpha-smooth muscle actin) antibodies are essential tools in biomedical research and diagnostics, targeting the protein encoded by the *ACTA2* gene. This gene produces α-smooth muscle actin (α-SMA), a cytoskeletal protein predominantly expressed in vascular and visceral smooth muscle cells, as well as myofibroblasts. α-SMA is critical for maintaining cell structure, motility, and contractile functions, playing key roles in processes like wound healing, tissue fibrosis, and vascular tone regulation.

ACTA2 antibodies are widely used to identify smooth muscle cells and myofibroblasts in tissues, aiding in the study of diseases involving abnormal smooth muscle proliferation or fibrosis, such as atherosclerosis, cancer stroma formation, and organ fibrosis (e.g., liver cirrhosis, pulmonary fibrosis). In cancer research, these antibodies help characterize tumor microenvironments by labeling cancer-associated fibroblasts. Additionally, they are employed in vascular pathology to assess smooth muscle cell differentiation in arterial remodeling or aneurysms.

Mutations in the *ACTA2* gene are linked to hereditary thoracic aortic aneurysms and dissections (TAAD), making these antibodies valuable for investigating genetic vascular disorders. In diagnostics, ACTA2 immunohistochemistry assists in differentiating tumors of smooth muscle origin (e.g., leiomyomas) from other mesenchymal neoplasms.

Commercially available ACTA2 antibodies are typically validated for techniques like immunohistochemistry, Western blotting, and immunofluorescence. Their specificity ensures reliable detection of α-SMA in formalin-fixed tissues or cultured cells, though cross-reactivity with other actin isoforms requires careful experimental controls.